FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311108317> ?p ?o ?g. }

• W4311108317 endingPage "5962" @default.
• W4311108317 startingPage "5962" @default.
• W4311108317 abstract "Eribulin is a microtubule destabilizer used in the treatment of triple-negative breast cancer (TNBC). Eribulin and other microtubule targeted drugs, such as the taxanes, have shared antimitotic effects, but differ in their mechanism of microtubule disruption, leading to diverse effects on cellular signaling and trafficking. Herein, we demonstrate that eribulin is unique from paclitaxel in its ability to enhance expression of the immunogenic cytokine interferon beta (IFNβ) in combination with STING agonists in both immune cells and TNBC models, including profound synergism with ADU-S100 and E7766, which are currently undergoing clinical trials. The mechanism by which eribulin enhances STING signaling is downstream of microtubule disruption and independent of the eribulin-dependent release of mitochondrial DNA. Eribulin did not override the requirement of ER exit for STING activation and did not inhibit subsequent STING degradation; however, eribulin significantly enhanced IRF3 phosphorylation and IFNβ production downstream of the RNA sensing pathway that converges on this transcription factor. Additionally, we found that eribulin enhanced the population of activated CD4+ T-cells in vivo when combined with either a STING agonist or tumor, demonstrating the ability to function as an immune adjuvant. We further interrogated the combination of eribulin with ADU-S100 in the MMTV-PyVT spontaneous murine mammary tumor model where we observed significant antitumor efficacy with combination treatment. Together, our findings demonstrate that microtubule targeted chemotherapeutics have distinct immunological effects and that eribulin’s ability to enhance innate immune sensing pathways supports its use in combination with immunotherapies, such as STING agonists, for the more effective treatment of TNBC and other malignancies." @default.
• W4311108317 created "2022-12-23" @default.
• W4311108317 creator A5020172955 @default.
• W4311108317 creator A5046557969 @default.
• W4311108317 creator A5049318512 @default.
• W4311108317 creator A5049484621 @default.
• W4311108317 creator A5060768848 @default.
• W4311108317 creator A5061082353 @default.
• W4311108317 date "2022-12-02" @default.
• W4311108317 modified "2023-10-13" @default.
• W4311108317 title "The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models" @default.
• W4311108317 cites W1551407310 @default.
• W4311108317 cites W1696775091 @default.
• W4311108317 cites W1720010186 @default.
• W4311108317 cites W1776390480 @default.
• W4311108317 cites W1968178474 @default.
• W4311108317 cites W1982276721 @default.
• W4311108317 cites W1982746572 @default.
• W4311108317 cites W2005452896 @default.
• W4311108317 cites W2009097375 @default.
• W4311108317 cites W2016263096 @default.
• W4311108317 cites W2020173029 @default.
• W4311108317 cites W2099610218 @default.
• W4311108317 cites W2127152525 @default.
• W4311108317 cites W2132413371 @default.
• W4311108317 cites W2133402546 @default.
• W4311108317 cites W2136274729 @default.
• W4311108317 cites W2141711186 @default.
• W4311108317 cites W2143523733 @default.
• W4311108317 cites W2165897342 @default.
• W4311108317 cites W2469317767 @default.
• W4311108317 cites W2588219496 @default.
• W4311108317 cites W2606504480 @default.
• W4311108317 cites W2617667835 @default.
• W4311108317 cites W2736376088 @default.
• W4311108317 cites W2753016107 @default.
• W4311108317 cites W2766581433 @default.
• W4311108317 cites W2773964572 @default.
• W4311108317 cites W2774323335 @default.
• W4311108317 cites W2781626404 @default.
• W4311108317 cites W2795589497 @default.
• W4311108317 cites W2799941962 @default.
• W4311108317 cites W2805465906 @default.
• W4311108317 cites W2806574348 @default.
• W4311108317 cites W2884264032 @default.
• W4311108317 cites W2887408433 @default.
• W4311108317 cites W2898224116 @default.
• W4311108317 cites W2901307735 @default.
• W4311108317 cites W2906951251 @default.
• W4311108317 cites W2920649201 @default.
• W4311108317 cites W2947489447 @default.
• W4311108317 cites W2947795259 @default.
• W4311108317 cites W2950182476 @default.
• W4311108317 cites W2954873842 @default.
• W4311108317 cites W2975223131 @default.
• W4311108317 cites W2982352864 @default.
• W4311108317 cites W2991440006 @default.
• W4311108317 cites W3006289883 @default.
• W4311108317 cites W3011178559 @default.
• W4311108317 cites W3011498764 @default.
• W4311108317 cites W3014389915 @default.
• W4311108317 cites W3036927511 @default.
• W4311108317 cites W3061136593 @default.
• W4311108317 cites W3083719420 @default.
• W4311108317 cites W3093056664 @default.
• W4311108317 cites W3111614282 @default.
• W4311108317 cites W3118999391 @default.
• W4311108317 cites W3128071834 @default.
• W4311108317 cites W3129646946 @default.
• W4311108317 cites W3133405534 @default.
• W4311108317 cites W3138947068 @default.
• W4311108317 cites W3145334405 @default.
• W4311108317 cites W3164702212 @default.
• W4311108317 cites W3168608273 @default.
• W4311108317 cites W3186881769 @default.
• W4311108317 cites W3195854721 @default.
• W4311108317 cites W3209465852 @default.
• W4311108317 cites W3210892875 @default.
• W4311108317 cites W4225910596 @default.
• W4311108317 cites W4226280775 @default.
• W4311108317 cites W4229079181 @default.
• W4311108317 doi "https://doi.org/10.3390/cancers14235962" @default.
• W4311108317 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36497445" @default.
• W4311108317 hasPublicationYear "2022" @default.
• W4311108317 type Work @default.
• W4311108317 citedByCount "4" @default.
• W4311108317 countsByYear W43111083172023 @default.
• W4311108317 crossrefType "journal-article" @default.
• W4311108317 hasAuthorship W4311108317A5020172955 @default.
• W4311108317 hasAuthorship W4311108317A5046557969 @default.
• W4311108317 hasAuthorship W4311108317A5049318512 @default.
• W4311108317 hasAuthorship W4311108317A5049484621 @default.
• W4311108317 hasAuthorship W4311108317A5060768848 @default.
• W4311108317 hasAuthorship W4311108317A5061082353 @default.
• W4311108317 hasBestOaLocation W43111083171 @default.
• W4311108317 hasConcept C121608353 @default.
• W4311108317 hasConcept C126322002 @default.
• W4311108317 hasConcept C127413603 @default.

• next